Stifel initiated coverage on Jade Biosciences with a new price target
$JBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $19.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/9/2025 | $28.00 | Buy | BTIG Research |
| 7/14/2025 | $16.00 | Buy | Jefferies |
| 6/16/2025 | $14.00 | Neutral → Buy | Guggenheim |
| 5/7/2025 | $17.00 | Outperform | Wedbush |
| 5/5/2025 | $19.00 | Buy | Stifel |
| 5/2/2025 | $10.00 | Buy | TD Cowen |
Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its potential as a best-in-class selective anti-APRIL monoclonal antibody for IgA nephropathy Initiated Phase 1 healthy volunteer study of JADE101; interim, biomarker-rich data expected in the first half of 2026 are anticipated to define dose and dose interval selection for patient trials Unveiled JADE201, a potentially best-in-class, half-life extended, afucosylated anti-BAFF receptor monoclonal antibody; first-in-human trial in rheumatoid arthritis expected to begin in the first half of 2026 with pot
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today presented two posters for JADE101, its investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2025. JADE101 is designed to selectively inhibit APRIL, a key driver of pathogenic IgA production in IgAN, a progressive autoimmune disease that frequently leads to end-stage kidney disease over a pati
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade"), (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Wedbush Rewind ASN Conference 2025 | November 10, 2025Fireside Chat: Monday, November 10 at 12:40 p.m. ETStifel Healthcare Conference | November 11–13, 2025Presentation: Wednesday, November 12 at 4:00 p.m. ETTD Cowen Immunology & Inflammation Virtual Summit | November 12-13, 2025Presentation: Thursday, November 13 at 3:00 p.m. ETJefferies Global Healthcare Conference - London | November 18–20, 202
BTIG Research initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $28.00
Jefferies initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $16.00
Guggenheim upgraded Jade Biosciences from Neutral to Buy and set a new price target of $14.00
4 - Jade Biosciences, Inc. (0001798749) (Issuer)
4 - Jade Biosciences, Inc. (0001798749) (Issuer)
3 - Jade Biosciences, Inc. (0001798749) (Issuer)
4 - Jade Biosciences, Inc. (0001798749) (Issuer)
S-1 - Jade Biosciences, Inc. (0001798749) (Filer)
10-Q - Jade Biosciences, Inc. (0001798749) (Filer)
8-K - Jade Biosciences, Inc. (0001798749) (Filer)
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less frequent subcutaneous dosing JADE201's high affinity binding and extended half-life enabled dose-dependent BAFF receptor occupancy and sustained B cell depletion in non-human primatesFirst-in-human trial in rheumatoid arthritis expected to begin in the first half of 2026; potential for broad opportunity across multiple autoimmune diseases validated by BAFF-R biologyCompany to host conference call and webcast today at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia,
Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic and pharmacodynamic profile with deep and sustained IgA reductions and the potential to support convenient subcutaneous dosing every eight weeks or longer First-in-human trial expected to begin second half 2025; biomarker-rich interim data in healthy volunteers expected first-half 2026 to inform patient dose and schedule Company to host conference call and webcast today, June 9, 2025, at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia, June
SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled "Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN," will be delivered